PTSD patients get extended relief: methylone study shows promise for Long-Term control
NCT ID NCT06237426
First seen Jun 27, 2026 ยท Last updated Jun 27, 2026
Summary
This study followed 44 people with PTSD who had already completed a prior methylone (TSND-201) trial. Over 52 weeks, researchers checked their symptoms and safety each month. If PTSD symptoms returned, participants could receive more methylone treatment. The goal was to see if the drug can safely manage PTSD over the long term.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 2
Tests whether the treatment actually works, and watches for side effects, in a larger group.
- Participants
-
44 people
The number who actually took part.
- Started
-
Mar 2024
- Finished
-
Oct 2025
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 71 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Participation in and successful completion of a prior Transcend-sponsored clinical trial with TSND-201. * Agree to not participate in any other interventional clinical trials for the duration of this study. * Willing and able to provide informed consent. Exclusion Criteria: * Had significant deviation(s)/non-compliance in parent study in the opinion of the Investigator which would deem them unsuitable for participation. * Change or development of any physical or psychological finding that would make participant unsuitable for study.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Post-traumatic stress disorder are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Cambridgeshire and Peterborough NHS Foundation Trust
Cambridge, England, United Kingdom
-
Cedar Clinical Research, Inc
Draper, Utah, 84020, United States
-
Clerkenwell Health
London, United Kingdom
-
Kings College
London, United Kingdom
-
La Nua Mental Health Centre
Galway, Ireland
-
Mirabilis Health
Belfast, Northern Ireland, United Kingdom
-
Mountain View Clinical Research
Denver, Colorado, 80209, United States
-
NHS Greater Glasgow and Clyde
Glasgow, Scotland, United Kingdom
-
Sunstone Medical
Rockville, Maryland, 20850, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can talk therapies quiet the trauma of violence?
- Can tailored brain stimulation quiet anxiety that drugs Can't?
- Mindfulness body scan may calm stress and inflammation after floods
- Brain imaging may expose a shared marker in PTSD and alcohol addiction
- Can magnetic pulses to the brain boost PTSD therapy?
- Could a Sleep-Focused therapy ease depression, anxiety, and PTSD?